efmarodocokin alfa + tacrolimus + methotrexate

This drug is a **combination** of three agents: efmarodocokin alfa, tacrolimus, and methotrexate. - **Efmarodocokin alfa** is a recombinant human fusion protein composed of interleukin-22 (IL-22) linked to the Fc region of human IgG4. It acts as an agonist of the interleukin 22 receptor (IL-22R), activating the IL-22 signaling pathway to promote epithelial repair and mucosal healing, particularly in inflammatory conditions without causing systemic immunosuppression. Efmarodocokin alfa has been primarily investigated for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, as well as other conditions like graft-versus-host disease, diabetic foot ulcers, and severe COVID-19 pneumonia[1][2][3][4][7][8][9]. - **Tacrolimus** is a calcineurin inhibitor immunosuppressant commonly used to prevent organ transplant rejection and treat autoimmune conditions. - **Methotrexate** is an antimetabolite and antifolate drug with immunosuppressive and anti-inflammatory properties, widely used in the management of autoimmune disorders and as chemotherapy for malignancies. This triple combination does not have a known, uniquely named product. Its use would offer both targeted epithelial repair/regeneration through efmarodocokin alfa and broad immunosuppression via tacrolimus and methotrexate.

Other names

IL-22FcIL22FcIL 22Fc